Director Zanotti Katherine S sale 4,608 shares of Exact Sciences Corporation [EXAS]

Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Exact Sciences Corporation shares valued at $208,005 were sold by Zanotti Katherine S on Jul 26. At $45.14 per share, Zanotti Katherine S sold 4,608 shares. The insider’s holdings dropped to 60,318 shares worth approximately $2.98 million following the completion of this transaction.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Also, Conroy Kevin T sold 7 shares, netting a total of over 285 in proceeds. Following the sale of shares at $40.75 each, the insider now holds 1,167,927 shares.

Before that, Zanotti Katherine S had sold 1,086 shares from its account. In a trade valued at $43,581, the Director traded Exact Sciences Corporation shares for $40.13 each. Upon closing the transaction, the insider’s holdings decreased to 1,086 shares, worth approximately $2.98 million.

As published in their initiating research note from Piper Sandler on June 03, 2022, Exact Sciences Corporation [EXAS] has been a Neutral and the price target has been revised to $50. This represents a 1.26% premium over Thursday’s closing price. Analysts at Raymond James downgraded the stock from ‘”a Strong buy”‘ to ‘”an Outperform”‘ outlook in a report released in early November. As of July 29, 2021, Stifel has reiterated its “Buy” rating for EXAS. Earlier on July 29, 2021, Oppenheimer resumed its rating. Their recommendation was “an Outperform” for EXAS stock.

Analyzing EXAS’s Price Performance

On Thursday, Exact Sciences Corporation [NASDAQ: EXAS] rose 3.74% to $49.37. The stock’s lowest price that day was $47.685, but it reached a high of $49.91 in the same session. During the last five days, there has been a surge of approximately 6.72%. Over the course of the year, Exact Sciences Corporation shares have dropped approximately -36.57%. Shares of the company reached a 52-week high of $84.46 on 01/18/22 and a 52-week low of $35.34 on 06/16/22. A 50-day SMA is recorded $44.99, while a 200-day SMA reached $67.30. Nevertheless, trading volume fell to 1.74 million shares from 2.5 million shares the previous day.

Support And Resistance Levels for Exact Sciences Corporation (EXAS)

According to the 24-hour chart, there is a support level at 48.07, which, if violated, would cause prices to drop to 46.76. In the upper region, resistance lies at 50.29. The next price resistance is at 51.21. RSI (Relative Strength Index) is 59.64 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 1.59, which suggests the price will increase in the coming days. Percent R is at 9.05%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.

Is Exact Sciences Corporation subject to short interest?

Stocks of Exact Sciences Corporation saw a sharp steep in short interest on Jul 14, 2022 dropping by -0.2 million shares to 10.74 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 10.94 million shares. A decline of -1.86% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 5 of the overall float, the days-to-cover ratio (short ratio) decline to 5.

Which companies own the most shares of Exact Sciences Corporation (EXAS)?

According to T. Rowe Price Associates, Inc. filings, the company currently owns 19,180,232 shares, which is about 10.90% of the total EXAS shares outstanding. The investor’s shares have appreciated by 5,392,099 from its previous 13-F filing of 13788133.0 shares. With the completion of the buy transaction, The Vanguard Group, Inc.’s stake is now worth $607,856,002. ARK Investment Management LLC acquire a 4.52% interest valued at $589.74 million while Wellington Management Co. LLP sold a -1,421,512 stake. A total of 168,317 shares of Exact Sciences Corporation were sold by BlackRock Fund Advisors during the quarter, and 176,261 were bought by Nikko Asset Management Co., Ltd. In its current portfolio, Capital Research & Management Co holds 5,487,009 shares valued at $216.13 million.

In terms of Exact Sciences Corporation share price expectations, FactSet research, analysts set an average price target of $71.63 in the next 12 months, up nearly 47.09% from the previous closing price of $47.59. Analysts anticipate Exact Sciences Corporation stock to reach $110.00 by 2022, with the lowest price target being $50.00. In spite of this, 19 analysts ranked Exact Sciences Corporation stock as a Buy at the end of 2022. On July 29, 2021, Canaccord Genuity assigned a price target of “a Buy” to the stock and reiterated coverage with a $160.


Please enter your comment!
Please enter your name here